How are the MMR vaccine and secukinumab related?
MMR (measles-mumps-rubella) is a live, attenuated vaccine. Secukinumab (Cosentyx) is an immunomodulating biologic that targets IL‑17A and can change immune responses. Using a live vaccine while on immune-modifying therapy is often treated as a higher-risk situation than giving non-live vaccines.
Can you get MMR if you take secukinumab?
Live vaccines like MMR are typically avoided during treatment with immunosuppressive/immune-modifying drugs unless a clinician specifically advises it. Many patients in this situation are guided to:
- Check whether they already received MMR doses before starting secukinumab.
- Use vaccination timing strategies (for example, giving necessary live vaccines before biologic therapy begins when possible).
- Follow an individualized plan from the prescribing clinician and the vaccination provider.
What do clinicians usually consider when deciding on MMR + secukinumab?
Decisions usually turn on whether the patient’s immune function is expected to be sufficiently intact to receive a live vaccine safely, and on the person’s overall risk factors. Clinicians also consider:
- The indication for secukinumab (for example, which condition you’re treating).
- Other immune-modifying medications used at the same time (combination therapy can increase risk).
- How long the person has been on secukinumab and whether they can defer vaccination until it’s safer.
If you can’t take MMR during secukinumab, what are the alternatives?
If MMR is not appropriate during treatment, clinicians may recommend:
- Completing MMR vaccination before starting biologic therapy (if you are not already fully vaccinated).
- Using non-live vaccines when available for related protection needs.
- Serology (blood tests) to check measles, mumps, and rubella immunity in some cases, depending on history and local guidance.
Why does secukinumab matter for MMR safety?
Secukinumab changes immune signaling by blocking IL‑17A, which can affect host defenses. Live vaccines rely on the immune system to control the attenuated organisms. That mismatch is why live vaccines are commonly deferred during biologic therapy.
Who should decide—rheumatology/dermatology, infectious disease, or a primary doctor?
In practice, the prescribing specialist managing secukinumab should be involved, because they can weigh treatment necessity and timing. The vaccination clinician (often primary care, pediatrics, or a public health clinic) also plays a role in implementing the plan.
What you should do next
Tell the clinician who manages your secukinumab the exact vaccine you’re asking about (MMR) and:
- Your secukinumab dose and schedule
- Whether you had MMR as a child and how many doses
- Any other immunosuppressing meds you take (including steroids)
If you share whether you’re an adult or child, how many MMR doses you’ve had, and when you started secukinumab, I can help narrow down the most likely clinical approach and what questions to ask your doctor.